Neogrand (Clodronate Disodium Tetrahydrate)

Clodronate, the active ingredient in Neogrand, is a bisphosphonate presented as an oral formulation for systemic use. It is employed to reduce bone resorption in conditions such as osteoporosis, Paget's disease, hypercalcemia of malignancy and bone metastases. GNH USA supplies Neogrand as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Neogrand is a bisphosphonate that targets excessive bone turnover in several skeletal disorders.

Osteoporosis: reduces bone resorption and helps maintain bone density in postmenopausal women and other at‑risk patients. Paget's disease of bone: normalises abnormal bone remodeling and alleviates associated pain. Hypercalcemia of malignancy: lowers elevated serum calcium levels caused by malignant disease. Bone metastases: limits skeletal complications by inhibiting osteoclast‑mediated bone loss.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea - Abdominal pain or dyspepsia - Constipation - Diarrhoea - Headache - Mild skin rash

Serious or Rare Side Effects: - Osteonecrosis of the jaw - Atypical femur fracture - Severe hypocalcaemia - Acute renal impairment - Anaphylactic or severe hypersensitivity reactions - Severe cutaneous adverse reactions (e.g., Stevens‑Johnson syndrome)

Before initiating therapy, several safety considerations should be addressed.

Renal function: assess baseline renal function and monitor periodically. Calcium/Vitamin D status: ensure adequate supplementation to minimise hypocalcaemia risk. Concurrent bisphosphonates: avoid using with other bisphosphonate agents. Pregnancy: prescribe only if clearly needed; data are limited. Dental procedures: complete invasive dental work before starting treatment. Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Clodronate may interact with several drug classes, requiring attention to timing and monitoring.

Major Interactions (Avoid): - Calcium‑containing antacids or supplements: reduce oral absorption of clodronate. - Aminoglycoside antibiotics: increase risk of renal toxicity when co‑administered. - Other nephrotoxic drugs: heightened potential for renal impairment.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect; monitor INR. - Systemic corticosteroids: may exacerbate bone loss; monitor bone density. - NSAIDs: can affect renal function; monitor renal parameters.